^Koide S, Onishi H, Hashimoto H, Kai T, Katayama M, Yamagami S (1995). "Effects of bifemelane hydrochloride on plasma neuropeptide Y, 3-methoxy-4-hydroxyphenylethylene glycol and 5-hydroxy-indole acetic acid concentrations in patients with cerebral infarction". Drugs Under Experimental and Clinical Research. 21 (5): 175–80.
PMID8846747.
^Shigemitsu T, Majima Y (1996). "Use of bifemelane hydrochloride in improving and maintaining the visual field of patients with glaucoma". Clinical Therapeutics. 18 (1): 106–13.
doi:
10.1016/S0149-2918(96)80183-4.
PMID8851457.
^Naoi M, Nomura Y, Ishiki R, Suzuki H, Nagatsu T (January 1988). "4-(O-benzylphenoxy)-N-methylbutylamine (bifemelane) and other 4-(O-benzylphenoxy)-N-methylalkylamines as new inhibitors of type A and B monoamine oxidase". Journal of Neurochemistry. 50 (1): 243–7.
doi:
10.1111/j.1471-4159.1988.tb13256.x.
PMID3335842.
S2CID35543291.
^Kovel'man IR, Tochilkin AI, Gorkin VZ (1991). "Structure and action of reversible monoamine oxidase inhibitors (review)". Pharmaceutical Chemistry Journal. 25 (8): 505–520.
doi:
10.1007/BF00777412.
ISSN0091-150X.
S2CID42477788.
^Dostert P (1994). "Can our knowledge of monoamine oxidase (MAO) help in the design of better MAO inhibitors?". Amine Oxidases: Function and Dysfunction. Vol. 41. pp. 269–279.
doi:
10.1007/978-3-7091-9324-2_35.
ISBN978-3-211-82521-1.
PMID7931236. For example, bifemelane [4-(O-benzylphenoxy)-N-methylbutylamine) is one of the few molecules in which both activities, reversible inhibition of MAO-A (Naoi et al., 1988) and inhibition of noradrenaline uptake (Egawa et al., 1983), although weak (IC50 = 10-6-10-7 M), coexist.{{
cite book}}: |journal= ignored (
help)
^Kondo Y, Ogawa N, Asanuma M, Matsuura K, Nishibayashi K, Iwata E (March 1996). "Preventive effects of bifemelane hydrochloride on decreased levels of muscarinic acetylcholine receptor and its mRNA in a rat model of chronic cerebral hypoperfusion". Neuroscience Research. 24 (4): 409–14.
doi:
10.1016/0168-0102(95)01017-3.
PMID8861111.
S2CID34313096.
^Koide S, Onishi H, Hashimoto H, Kai T, Katayama M, Yamagami S (1995). "Effects of bifemelane hydrochloride on plasma neuropeptide Y, 3-methoxy-4-hydroxyphenylethylene glycol and 5-hydroxy-indole acetic acid concentrations in patients with cerebral infarction". Drugs Under Experimental and Clinical Research. 21 (5): 175–80.
PMID8846747.
^Shigemitsu T, Majima Y (1996). "Use of bifemelane hydrochloride in improving and maintaining the visual field of patients with glaucoma". Clinical Therapeutics. 18 (1): 106–13.
doi:
10.1016/S0149-2918(96)80183-4.
PMID8851457.
^Naoi M, Nomura Y, Ishiki R, Suzuki H, Nagatsu T (January 1988). "4-(O-benzylphenoxy)-N-methylbutylamine (bifemelane) and other 4-(O-benzylphenoxy)-N-methylalkylamines as new inhibitors of type A and B monoamine oxidase". Journal of Neurochemistry. 50 (1): 243–7.
doi:
10.1111/j.1471-4159.1988.tb13256.x.
PMID3335842.
S2CID35543291.
^Kovel'man IR, Tochilkin AI, Gorkin VZ (1991). "Structure and action of reversible monoamine oxidase inhibitors (review)". Pharmaceutical Chemistry Journal. 25 (8): 505–520.
doi:
10.1007/BF00777412.
ISSN0091-150X.
S2CID42477788.
^Dostert P (1994). "Can our knowledge of monoamine oxidase (MAO) help in the design of better MAO inhibitors?". Amine Oxidases: Function and Dysfunction. Vol. 41. pp. 269–279.
doi:
10.1007/978-3-7091-9324-2_35.
ISBN978-3-211-82521-1.
PMID7931236. For example, bifemelane [4-(O-benzylphenoxy)-N-methylbutylamine) is one of the few molecules in which both activities, reversible inhibition of MAO-A (Naoi et al., 1988) and inhibition of noradrenaline uptake (Egawa et al., 1983), although weak (IC50 = 10-6-10-7 M), coexist.{{
cite book}}: |journal= ignored (
help)
^Kondo Y, Ogawa N, Asanuma M, Matsuura K, Nishibayashi K, Iwata E (March 1996). "Preventive effects of bifemelane hydrochloride on decreased levels of muscarinic acetylcholine receptor and its mRNA in a rat model of chronic cerebral hypoperfusion". Neuroscience Research. 24 (4): 409–14.
doi:
10.1016/0168-0102(95)01017-3.
PMID8861111.
S2CID34313096.